1
|
Ailuno G, Balboni A, Caviglioli G, Lai F, Barbieri F, Dellacasagrande I, Florio T, Baldassari S. Boron Vehiculating Nanosystems for Neutron Capture Therapy in Cancer Treatment. Cells 2022; 11:cells11244029. [PMID: 36552793 PMCID: PMC9776957 DOI: 10.3390/cells11244029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2022] [Revised: 12/09/2022] [Accepted: 12/11/2022] [Indexed: 12/15/2022] Open
Abstract
Boron neutron capture therapy is a low-invasive cancer therapy based on the neutron fission process that occurs upon thermal neutron irradiation of 10B-containing compounds; this process causes the release of alpha particles that selectively damage cancer cells. Although several clinical studies involving mercaptoundecahydro-closo-dodecaborate and the boronophenylalanine-fructose complex are currently ongoing, the success of this promising anticancer therapy is hampered by the lack of appropriate drug delivery systems to selectively carry therapeutic concentrations of boron atoms to cancer tissues, allowing prolonged boron retention therein and avoiding the damage of healthy tissues. To achieve these goals, numerous research groups have explored the possibility to formulate nanoparticulate systems for boron delivery. In this review. we report the newest developments on boron vehiculating drug delivery systems based on nanoparticles, distinguished on the basis of the type of carrier used, with a specific focus on the formulation aspects.
Collapse
Affiliation(s)
- Giorgia Ailuno
- Department of Pharmacy, University of Genova, 16147 Genova, Italy
- Correspondence: (G.A.); (T.F.)
| | - Alice Balboni
- Department of Pharmacy, University of Genova, 16147 Genova, Italy
| | | | - Francesco Lai
- Department of Life and Environmental Sciences (DiSVA), University of Cagliari, 09124 Cagliari, Italy
| | - Federica Barbieri
- Department of Internal Medicine, University of Genova, 16132 Genova, Italy
| | | | - Tullio Florio
- Department of Internal Medicine, University of Genova, 16132 Genova, Italy
- IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy
- Correspondence: (G.A.); (T.F.)
| | - Sara Baldassari
- Department of Pharmacy, University of Genova, 16147 Genova, Italy
| |
Collapse
|
2
|
Nelyubin AV, Klyukin IN, Zhdanov AP, Grigor’ev MS, Zhizhin KY, Kuznetsov NT. Synthesis of Substituted Derivatives of closo-Decaborate Anion with a Peptide Bond: The Way towards Designing Biologically Active Boron-Containing Compounds. RUSS J INORG CHEM+ 2020. [DOI: 10.1134/s003602361912012x] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
3
|
|
4
|
Sato S, Ishii S, Nakamura H. Development of Albumin-closo
-Dodecaborate Conjugates as Boron Carriers for Neutron-Capture Therapy by Ru(bpy)3
-Photocatalyzed Modification of Tyrosine. Eur J Inorg Chem 2017. [DOI: 10.1002/ejic.201700578] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Shinichi Sato
- Laboratory for Chemistry and Life Science; Institute of Innovative Research; Tokyo Institute of Technology; R1-13, 4259 Nagatsuta-cho, Midori-ku 226-8503 Yokohama Japan
| | - Satomu Ishii
- Laboratory for Chemistry and Life Science; Institute of Innovative Research; Tokyo Institute of Technology; R1-13, 4259 Nagatsuta-cho, Midori-ku 226-8503 Yokohama Japan
| | - Hiroyuki Nakamura
- Laboratory for Chemistry and Life Science; Institute of Innovative Research; Tokyo Institute of Technology; R1-13, 4259 Nagatsuta-cho, Midori-ku 226-8503 Yokohama Japan
| |
Collapse
|
5
|
Wang J, Wu W, Jiang X. Nanoscaled boron-containing delivery systems and therapeutic agents for cancer treatment. Nanomedicine (Lond) 2015; 10:1149-63. [DOI: 10.2217/nnm.14.213] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
Significant efforts have recently been made to develop nanoscaled boron-containing delivery systems for improving drug delivery in cancer therapy. On one hand, borate ester chemistry has shown importance in ligand-mediated tumor targeting owing to the recognition ability of boronic acid to polyol residues in cell membranes. In particular, the phenylboronic acid-functionalized nanocarriers for specific targeting to sialic acid groups which are overexpressed on tumor cells have made great achievements. On the other hand, nanoscaled boron neutron capture therapy agents show growing potential in efficiently transporting boron to tumor. The current review outlines the recent developments in the application of borate ester chemistry in tumor targeting by nanoparticles, then summarizes recent work on the development of boron-based nanomaterials as boron neutron capture therapy agents.
Collapse
Affiliation(s)
- Jing Wang
- Department of Polymer Science & Engineering, College of Chemistry & Chemical Engineering, Nanjing University, Nanjing 210093, People's Republic of China
| | - Wei Wu
- Department of Polymer Science & Engineering, College of Chemistry & Chemical Engineering, Nanjing University, Nanjing 210093, People's Republic of China
| | - Xiqun Jiang
- Department of Polymer Science & Engineering, College of Chemistry & Chemical Engineering, Nanjing University, Nanjing 210093, People's Republic of China
| |
Collapse
|
6
|
Carboranyl-porphyrazines and derivatives for boron neutron capture therapy: From synthesis to in vitro tests. Coord Chem Rev 2013. [DOI: 10.1016/j.ccr.2013.03.035] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
7
|
Koganei H, Ueno M, Tachikawa S, Tasaki L, Ban HS, Suzuki M, Shiraishi K, Kawano K, Yokoyama M, Maitani Y, Ono K, Nakamura H. Development of high boron content liposomes and their promising antitumor effect for neutron capture therapy of cancers. Bioconjug Chem 2012; 24:124-32. [PMID: 23214414 DOI: 10.1021/bc300527n] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Mercaptoundecahydrododecaborate (BSH)-encapsulating 10% distearoyl boron lipid (DSBL) liposomes were developed as a boron delivery vehicle for neutron capture therapy. The current approach is unique because the liposome shell itself possesses cytocidal potential in addition to its encapsulated agents. BSH-encapsulating 10% DSBL liposomes have high boron content (B/P ratio: 2.6) that enables us to prepare liposome solution with 5000 ppm boron concentration. BSH-encapsulating 10% DSBL liposomes displayed excellent boron delivery efficacy to tumor: boron concentrations reached 174, 93, and 32 ppm at doses of 50, 30, and 15 mg B/kg, respectively. Magnescope was also encapsulated in the 10% DSBL liposomes and the real-time biodistribution of the Magnescope-encapsulating DSBL liposomes was measured in a living body using MRI. Significant antitumor effect was observed in mice injected with BSH-encapsulating 10% DSBL liposomes even at the dose of 15 mg B/kg; the tumor completely disappeared three weeks after thermal neutron irradiation ((1.5-1.8) × 10(12) neutrons/cm(2)). The current results enabled us to reduce the total dose of liposomes to less than one-fifth compared with that of the BSH-encapsulating liposomes without reducing the efficacy of boron neutron capture therapy (BNCT).
Collapse
Affiliation(s)
- Hayato Koganei
- Department of Chemistry, Faculty of Science, Gakushuin University, Mejiro, Toshima-ku, Tokyo 171-8588, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Ueno M, Ban HS, Nakai K, Inomata R, Kaneda Y, Matsumura A, Nakamura H. Dodecaborate lipid liposomes as new vehicles for boron delivery system of neutron capture therapy. Bioorg Med Chem 2010; 18:3059-65. [PMID: 20371186 DOI: 10.1016/j.bmc.2010.03.050] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2010] [Revised: 03/17/2010] [Accepted: 03/18/2010] [Indexed: 10/19/2022]
Abstract
Closo-dodecaborate lipid liposomes were developed as new vehicles for boron delivery system (BDS) of neutron capture therapy. The current approach is unique because the liposome shell itself possesses cytocidal potential in combination with neutron irradiation. The liposomes composed of closo-dodecaborate lipids DSBL and DPBL displayed high cytotoxicity with thermal neutron irradiation. The closo-dodecaborate lipid liposomes were taken up into the cytoplasm by endocytosis without degradation of the liposomes. Boron concentration of 22.7 ppm in tumor was achieved by injection with DSBL-25% PEG liposomes at 20mg B/kg. Promising BNCT effects were observed in the mice injected with DSBL-25% PEG liposomes: the tumor growth was significantly suppressed after thermal neutron irradiation (1.8 x 10(12)neutrons/cm(2)).
Collapse
Affiliation(s)
- Manabu Ueno
- Department of Chemistry, Faculty of Science, Gakushuin University, Mejiro, Toshima-ku, Tokyo 171-8588, Japan
| | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
Summary
Treatment of cancer using boron neutron capture therapy requires the specific accumulation of a relatively high concentration of 10B into tumor cells or tumor vasculature. In this paper, targeted liposomes were evaluated as carriers of 10B for this purpose. Na2
10B12H12 was successfully encapsulated into liposomes and relatively high amounts of 10B could be targeted to ovarian carcinoma cells (OVCAR-3) and endothelial cells (HUVEC). This was achieved by coupling a monoclonal antibody or an RGD peptide to the liposomes. The results suggest that targeted liposomes could meet the requirements of successful neutron capture therapy in the near future.
Collapse
|
10
|
Martini G, Ciani L. Electron spin resonance spectroscopy in drug delivery. Phys Chem Chem Phys 2009; 11:211-54. [DOI: 10.1039/b808263d] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
11
|
Yanagië H, Ogata A, Sugiyama H, Eriguchi M, Takamoto S, Takahashi H. Application of drug delivery system to boron neutron capture therapy for cancer. Expert Opin Drug Deliv 2008; 5:427-43. [PMID: 18426384 DOI: 10.1517/17425247.5.4.427] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
BACKGROUND Tumor cell destruction in boron neutron capture therapy (BNCT) is due to the nuclear reaction between (10)B and thermal neutrons ((10)B + (1)n --> (7)Li + (4)He (alpha) + 2.31 MeV (93.7 %)/2.79 MeV (6.3 %)). The resulting lithium ions and alphaparticles are high linear energy transfer (LET) particles which give a high biological effect. Their short range in tissue (5 - 9 mum) restricts radiation damage to those cells in which boron atoms are located at the time of neutron irradiation. BNCT has been applied clinically for the treatment of malignant brain tumors, malignant melanoma, head and neck cancer and hepatoma. Sodium mercaptoundecahydro-dodecaborate (Na(2)(10)B(12)H(11)SH: BSH) and borono-phenylalanine ((10)BPA) are currently being used in clinical treatments. These low molecule compounds are easily cleared from cancer cells and blood, so high accumulation and selective delivery of boron compounds into tumor tissues and cancer cells are most important to achieve effective BNCT and to avoid damage to adjacent healthy cells. OBJECTIVE In order to achieve the selective delivery of boron atoms to cancer cells, a drug delivery system (DDS) is an attractive intelligent technology for targeting and controlled release of drugs. METHODS We performed literature searches related to boron delivery systems in vitro and in vivo. RESULTS We describe several DDS technologies for boron delivery to cancer tissues and cancer cells from the past to current status. We are convinced that it will be possible to use liposomes, monoclonal antibodies and WOW emulsions as boron delivery systems for BNCT clinically in accordance with the preparation of good commercial product (GCP) grade materials.
Collapse
Affiliation(s)
- Hironobu Yanagië
- University of Tokyo, Department of Nuclear Engineering and Management, Graduate School of Engineering, Tokyo, Japan.
| | | | | | | | | | | |
Collapse
|
12
|
Ciani L, Ristori S, Bonechi C, Rossi C, Martini G. Effect of the preparation procedure on the structural properties of oligonucleotide/cationic liposome complexes (lipoplexes) studied by electron spin resonance and Zeta potential. Biophys Chem 2007; 131:80-7. [PMID: 17950520 DOI: 10.1016/j.bpc.2007.09.011] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2007] [Revised: 09/12/2007] [Accepted: 09/13/2007] [Indexed: 10/22/2022]
Abstract
Lipoplexes with different surface charge were prepared from a short oligonucleotide (20 mer, dsAT) inserted into liposomes of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and 1,2-dioleoyl-sn-glycero-3-phospho-ethanolamine (DOPE). The starting liposomes were prepared by two different procedures, i.e. progressive dsAT addition starting from plain liposomes (titration) and direct mixing of dsAT with pure liposomes (point to point preparation). Lipoplexes were characterized from a molecular point of view by Electron Spin Resonance (ESR) of a cationic spin probe and by Nuclear Magnetic Resonance. Structural and surface features were analysed by Zeta potential (zeta) measurements and Cryo-TEM micrographs. The complete set of results allowed to demonstrate that: i) the interactions between dsAT and cationic lipids were strong and occurred at the liposome surface; ii) the overall shape and physicochemical properties of liposomes did not change when short nucleic acid fragments were added before surface charge neutralization; iii) the bilayer structure of the lipids in lipoplexes was substantially preserved at all charge ratios; iv) the physical status of lipoplexes with electrical charge far from neutrality did not depend on the preparation method.
Collapse
Affiliation(s)
- Laura Ciani
- Department of Chemistry & CSGI, University of Florence, Via della Lastruccia 3, 50019 Sesto F no, Firenze, Italy
| | | | | | | | | |
Collapse
|
13
|
Thirumamagal BTS, Zhao XB, Bandyopadhyaya AK, Naranyanasamy S, Johnsamuel J, Tiwari R, Golightly DW, Patel V, Jehning BT, Backer MV, Barth RF, Lee RJ, Backer JM, Tjarks W. Receptor-Targeted Liposomal Delivery of Boron-Containing Cholesterol Mimics for Boron Neutron Capture Therapy (BNCT). Bioconjug Chem 2006; 17:1141-50. [PMID: 16984121 DOI: 10.1021/bc060075d] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Liposomes have been a main focus of tumor-selective boron delivery strategies in boron neutron capture therapy (BNCT), a binary method for the treatment of cancer that is based on the nuclear reaction between boron atoms and low-energy thermal neutrons. Three novel carboranyl cholesterol derivatives were prepared as lipid bilayer components for the construction of nontargeted and receptor-targeted boronated liposomes for BNCT. A major structural feature of these novel boronated cholesterol mimics is the replacement of the B and the C ring of cholesterol with a carborane cluster. Computational analyses indicated that all three boronated compounds have structural features and physicochemical properties that are very similar to those of cholesterol. One of the synthesized boronated cholesterol mimics was stably incorporated into non-, folate receptor (FR)-, and vascular endothelial growth factor receptor-2 (VEGFR-2)-targeted liposomes. No major differences were found in appearance, size distribution, and lamellarity between conventional dipalmitoylphosphatidylcholine (DPPC)/cholesterol liposomes, nontargeted, and FR-targeted liposomal formulations of this carboranyl cholesterol derivative. FR-targeted boronated liposomes were taken up extensively in FR overexpressing KB cells in vitro, and the uptake was effectively blocked in the presence of free folate. In contrast, a boronated cholesterol mimic incorporated into nontargeted liposomes showed significantly lower cellular uptake. There was no apparent in vitro cytotoxicity in FR overexpressing KB cells and VEGFR-2 overexpressing 293/KDR cells when these were incubated with boronated FR- and (VEGFR-2)-targeted liposomes, respectively, although the former accumulated extensively in KB cells and the latter effectively interacted with VEGFR-2 by causing autophosphorylation and protecting 293/KDR cells from SLT (Shiga-like toxin)-VEGF cytotoxicity.
Collapse
Affiliation(s)
- B T S Thirumamagal
- Division of Medicinal Chemistry & Pharmacognosy, The Ohio State University, Columbus, 43210, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Rossi S, Schinazi RF, Martini G. ESR as a valuable tool for the investigation of the dynamics of EPC and EPC/cholesterol liposomes containing a carboranyl-nucleoside intended for BNCT. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES 2005; 1712:81-91. [PMID: 15904892 DOI: 10.1016/j.bbamem.2005.04.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/26/2005] [Revised: 04/05/2005] [Accepted: 04/11/2005] [Indexed: 11/16/2022]
Abstract
Electron Spin Resonance (ESR) spectroscopy of long-chain nitroxides (5-, 7-, and 16-doxyl stearic acid) has been used to evaluate the perturbations induced by beta-5-o-carboranyl-2'-deoxyuridine (CDU) on the structure and dynamics of egg phosphatidylcholine (EPC) and EPC/cholesterol liposomes. Loaded liposomes are intended for the use in Boron Neutron Capture Therapy (BNCT). From a detailed analysis of the motional and order parameters determining the ESR line shape as a function of temperature and of CDU content in liposomes, an increased order and a hindered motion of the phospholipid membranes resulted in the presence of increasing CDU concentration. This occurred particularly at the liposome surface level. Both higher ordering and increased rigidity of the membrane lipids were the result of the constraints exerted by the embedded carboranyl-nucleoside.
Collapse
Affiliation(s)
- Simona Rossi
- Dipartimento di Chimica, Università di Firenze, Sesto Fiorentino, Italy.
| | | | | |
Collapse
|
15
|
Boron neutron capture therapy. ACTA ACUST UNITED AC 2005. [DOI: 10.1016/s0169-3158(06)80006-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
|